|
|
Volumn 196, Issue 2, 2002, Pages 183-190
|
|
Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations;Maladie de Fabry (déficit en alpha-galactosidase A): innovations thérapeutiques récentes.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 DEOXYNOJIRIMYCIN;
ALPHA GALACTOSIDASE;
ANALGESIC AGENT;
ANTIHYPERTENSIVE AGENT;
DRUG DERIVATIVE;
ENZYME INHIBITOR;
HYBRID PROTEIN;
N BUTYLDEOXYGALACTONOJIRIMYCIN;
N-BUTYLDEOXYGALACTONOJIRIMYCIN;
ADENOVIRUS;
ANIMAL;
CLINICAL TRIAL;
DISEASE MODEL;
ENZYMOLOGY;
FABRY DISEASE;
GENE THERAPY;
GENE VECTOR;
GENETICS;
HUMAN;
KIDNEY DISEASE;
KIDNEY TRANSPLANTATION;
MOUSE;
MOUSE MUTANT;
MULTIMODALITY CANCER THERAPY;
RENAL REPLACEMENT THERAPY;
RETROVIRUS;
REVIEW;
X CHROMOSOME;
1-DEOXYNOJIRIMYCIN;
ADENOVIRIDAE;
ALPHA-GALACTOSIDASE;
ANALGESICS;
ANIMALS;
ANTIHYPERTENSIVE AGENTS;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
DISEASE MODELS, ANIMAL;
ENZYME INHIBITORS;
FABRY DISEASE;
GENE THERAPY;
GENETIC VECTORS;
HUMANS;
KIDNEY DISEASES;
KIDNEY TRANSPLANTATION;
MICE;
MICE, KNOCKOUT;
RECOMBINANT FUSION PROTEINS;
RENAL DIALYSIS;
RETROVIRIDAE;
X CHROMOSOME;
MLCS;
MLOWN;
|
|
EID: 0036355836
PISSN: 12950661
EISSN: None
Source Type: Journal
DOI: 10.1051/jbio/2002196020183 Document Type: Review |
|
Times cited : (19)
|
|
References (41)
|
